Free Trial
NASDAQ:TMDX

TransMedics Group Q1 2025 Earnings Report

TransMedics Group logo
$90.45 -1.56 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$91.37 +0.92 (+1.01%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group EPS Results

Actual EPS
N/A
Consensus EPS
$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

TransMedics Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$123.39 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

TransMedics Group Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

TransMedics Group Earnings Headlines

Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $122.70
The collapse has already started
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
TransMedics Group (TMDX) Gets a Hold from Needham
See More TransMedics Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TransMedics Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your email.

About TransMedics Group

TransMedics Group (NASDAQ:TMDX), a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

View TransMedics Group Profile

More Earnings Resources from MarketBeat